• Uni-Bio Science Group flagged a sharp profit drop, guiding to net profit of about HK$ 30 million for H1 ended June 30, 2026.
• That compares with net profit of HK$ 75.96 million a year earlier.
• Higher PRC VAT on biological products, rising to 13% from 3%, hit biological drug sales.
• New volume-based procurement bid prices weighed on revenue for selected drugs.
• R&D spending, business development costs increased; cash and cash equivalents were at least HK$ 140 million at June 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12276939), on August 07, 2026, and is solely responsible for the information contained therein.